

Presentation 9 – James Baraniuk

**“A Chronic Fatigue Syndrome Related
Proteome in Cerebrospinal Fluid”**

Baraniuk JN,* Casado B,*§ Maibach H,*
Clauw DJ,*† Pannell LK,‡ Hess S.‡

BMC Neurology 5:22, 2005

*Georgetown University
§Swiss Federal Institute of Technology
†University of Michigan
‡NIDDK


DNA → mRNA → Protein



| <u>Genomics</u> | <u>mRNA Microarray</u> | <u>Proteomics</u> |
|--|--|--|
| Examine genes in DNA Single point mutations (SNPs) | Examine mRNA expressed at one point in time | Examine the proteins in a cell, tissue, fluid sample |
| What you are born with | mRNA is made into proteins | Proteins determine what is happening now |
| Potential Risk Factors | Different expression between “Disease” and “Control” | Comparison of “Disease” and “Control” |
| Diathesis | | Disease-related set of proteins or “Proteome” |
| Population Studies | Gene microarrays | |



Outline

- Cerebrospinal fluid (CSF)
- Study design
- Patient groups for proteomic analysis
- Tandem Mass Spectrometry (MS-MS), Bioinformatics
- Statistical Analysis
- Implications
- Funding Sources
 - United States Department of Defense Award DAMD 170020018
 - Public Health Service Award RO1 AI42403
 - General Clinical Research Center Program 1 M01-RR13297-01A1
- Site:
 - Georgetown University G-CRC and Proteomics Laboratory

Where Does Cerebrospinal Fluid Come From?







Georgetown “CMI” Study; Dan Clauw, PI

- **Recruited Subject Groups:**
 - **Veterans** with Persian Gulf Illness (PGI, GWI, CMI)
 - **Fibromyalgia** (FM; positive controls, ACR Criteria)
 - **Healthy controls** (HC)

- **Multidimensional Evaluation:**
 - Psychiatric, psychometric
 - HPA axis, hyperalgesia, fMRI
 - Autonomic and exercise responses
 - Blood biomarker and lumbar puncture
 - Assess for PGI, CFS, FM, MCS, IBS, and other syndromes

Cerebrospinal Fluid

- One anesthetist for reproducible technique
- Lumbar punctures at same time of the morning
- Narrow gauge (22G) catheters
- Few, mild adverse events (headaches)


- Tubes 2, 3, 4
- Centrifuged to remove cells
- Aprotinin (antiprotease) added
- Frozen at -80°C

2 Distinct Proteomic Analysis Groups

- | | |
|---|--|
| <ul style="list-style-type: none">• <u>Cohort 1:</u>• <u>Pooled Samples</u> • Healthy controls (HC)• PGI• CFS • N = 10 CSF specimens per group• 3 samples | <ul style="list-style-type: none">• <u>Cohort 2:</u>• <u>Individual Samples</u> • N= 12 HC• N = 9 "CFS" • 21 separate proteomic analyses• Statistical comparisons |
|---|--|

Final overall analysis of all HC vs. all CFS/PGI/FM ("CFS")

Overlapping Syndromes: "Psycho – Semantics" of Case Definitions



| Cohort Characteristics | | | | | |
|--------------------------------------|----------|------------------------|--------------------|---------------------------------------|--------------------------------------|
| Group | N | Age (yr) | Male | CESD Affective Dysfunction | Pain Threshold (kg) |
| COHORT 1 (Pooled Samples) | | | | | |
| HC Pool | 10 | 34.4 (29.1 to 39.7) | 80% | 4.3 (0.6 to 7.9) | 7.69 (5.72 to 9.65) |
| CFS Pool | 10 | 39.9 (34.3 to 45.5) | 20% ^{***} | 17.6 ^{***} (12.1 to 23.0) | 4.01 ^{**} (2.86 to 5.16) |
| PGI Pool | 10 | 43.5 (38.7 to 48.3) | 60% | 18.1 ^{**} (8.7 to 27.5) | 4.89 [*] (3.64 to 6.14) |
| COHORT 2 (Individual Samples) | | | | | |
| HC | 12 | 41.3 (33.6 to 48.9) | 75% | - | 7.17 (5.71 to 8.64) |
| CFS | 9 | 39.1 (32.2 to 46.0) | 33% | - | 4.97 [§] (3.75 to 6.19) |

^{*}p<0.05, ^{**}p<0.01, ^{***}p<0.001 compared to HC Pool results; [§]p<0.05 compared to HC individuals; ANOVA followed by Student's t-tests.

Clinical Summary

- CFS / PGI / FM groups had extensive overlap, with only 2 “pure” PGI subjects.
- CFS was the single most common “syndrome” in these subjects.
- CFS / PGI / FM subjects had:
 - Worse QOL (SF-36), fatigue (MFI), and affective dysfunction (CESD)
 - Lower pain thresholds (systemic hyperalgesia)

Proteomics: Proteins → Peptides

- CSF proteins digested into peptides with trypsin
- Trypsin peptides separated by capillary liquid chromatography (CapLC)
- → Tandem mass spectrometry (MS-MS)
 - 1st MS: quadrupole MS to separate peptide ions
 - 2nd MS-MS: time-of-flight MS to sequence peptides

Peptide Sequences to Protein Functions

- 2nd MS-MS spectra → sequence each peptide
- Peptide sequences → MASCOT software
- MASCOT → protein identification for each sample

- Protein functions and interactions →
- Protein Information Resource (PIR)
- <http://pir.georgetown.edu>

Proteins from Pooled Samples
(Cohort 1)

Proteins that were detected in **BOTH** the
pooled PGI and pooled CFS specimens

AND

were **ABSENT** from the pooled healthy
control specimen

defined the

“Cohort 1 CFS-related Proteome”

Cohort 1 Pooled CFS” Proteome

Cohort 1
“Pooled CFS” Proteome

α 2-Macroglobulin
Ceruloplasmin / ferroxidase II
Orosomuroid 2
Autotaxin / phosphodiesterase 1 α
Amyloid precursor-like protein 1
BEHAB

Complement C4A, C4B
PEDF
Gelsolin
Carnosine dipeptidase 1 (CNDP1)

Proteins from Individual Samples **(Cohort 2)**

- **Statistical analysis**
- Lists of proteins from each individual sample
 - **Multilogistic analysis and modeling (GLM)**
 - **Support Vector Machine Learning (SVM-PSO-LOO)**
- Identify the unique set of proteins found in CFS/PGI/FM but not healthy controls

Proteins from Individual Samples **(Cohort 2)**

- **“Detectability”:**
 - All proteins detected and identified by 2nd MS-MS.
 - Peptides identified above the lower limits of detection
- **Frequency of detection:**
 - The frequencies or prevalences of each protein in the healthy control group (HC) and CFS/PGI/FM group.
 - Qualitative analysis (ANOVA).
- Proteins detected significantly more frequently in CFS/PGI/FM than HC group formed the:
“CFS/PGI/FM related proteome”.

Cohort 2 “CFS/PGI/FM” Proteome

**Cohort 2
 “CFS” Proteome**

Keratin 16
 α2-Macroglobulin
 Ceruloplasmin / ferroxidase II
 Orosomuroid 2
 Autotaxin / phosphodiesterase 1α
 Amyloid precursor-like protein 1
 BEHAB
 Keratin 6C
 Keratin 17
 Orosomuroid 1
 Keratin 10
 Complement C4B
 PEDF
 Gelsolin
 Carnosine dipeptidase 1 (CNDP1)
 Keratin 14

Comparison of Cohort 1 and 2 Proteomes

| Cohort 1 “Pooled CFS” Proteome | Cohort 2 “CFS” Proteome |
|---|---|
| | Keratin 16 |
| α2-Macroglobulin Ceruloplasmin / ferroxidase II Orosomuroid 2 Autotaxin / phosphodiesterase 1α Amyloid precursor-like protein 1 BEHAB | α2-Macroglobulin Ceruloplasmin / ferroxidase II Orosomuroid 2 Autotaxin / phosphodiesterase 1α Amyloid precursor-like protein 1 BEHAB |
| | Keratin 6C Keratin 17 Orosomuroid 1 Keratin 10 |
| Complement C4A, C4B PEDF Gelsolin Carnosine dipeptidase 1 (CNDP1) | Complement C4B PEDF Gelsolin Carnosine dipeptidase 1 (CNDP1) |
| | Keratin 14 |

Odds of matching 10 proteins: 10^{-15}

Multilogistic Proteomic Biosignature (B1/5) Model

IF any 1 of these 5 proteins was detected:

Keratin 16
 α 2-Macroglobulin
Orosomuroid 2
Autotaxin / phosphodiesterase 1 α
Pigment Epithelium Derived Factor (PEDF)

THEN

CFS was present with
OR=34.5
(1.49 to 809.61; p=0.0072, Fisher's Exact test)

AND

CFS status = gender + (B1/5)
80% concordance

First objectively defined, predictive model
for these illnesses.

Pathophysiological Implications

Protease – Antiprotease
Imbalance

- α 2-Macroglobulin
- Orosomuroid 1 and 2

Structural Injury

- Gelsolin (apoptosis)
- Amyloid APLP1
- C4B (C3)

Oxidant Injury

- Ceruloplasmin
- Carnosine dipeptidase 1

Vascular Dysregulation



- Autotaxin
- Pigment Epithelium Derived Factor (EPDF)
- Vasoconstriction (ischemia)
- Endothelial proliferation (repair)



Leptomeningeal Activation



- Keratins 4, 10, 16, 17


Structural Repair

- Brain-enhanced hyaluronan binding (BEHAB)










Conclusions: "Psycho-Semantics"

- Subjects met case designation criteria for several syndromes.
 - CFS / PGI / FM / IBS / MCS / hyperalgesia / dysautonomia . . .
- The high degree of overlap suggests that some pathophysiological mechanisms may be shared between syndromes.
- The patients are not "psycho" (the doctors are).

Conclusions: Proteomic Modeling

- Proteomic analysis of 2 different cohorts of CFS/PGI/FM subjects qualitatively identified a subset of cerebrospinal fluid proteins.
 - “CFS/PGI/FM Proteome”
- Multilogistic modeling identified a biosignature (**B1/5**) where the presence of 1 out of 5 proteins was sufficient to predict CFS status.
- This is the first objectively defined model predicting CFS/PGI/FM status.
 - OR=34.5; 80% concordance

Conclusions: Reversible, Non-Lethal CAA?



| <u>DNA → mRNA → Protein</u> | | |
|--|---|---|
| <u>Genomics</u> | <u>mRNA Microarray</u> | <u>Proteomics</u> |
| <ul style="list-style-type: none"> •Examine genes in DNA •Single point mutations (SNPs) •What you are born with •Potential •Risk Factors •Diathesis •<u>Population Studies</u> | <ul style="list-style-type: none"> •Examine mRNA expressed at one point in time •mRNA is made into proteins •Different expression between "Disease" and "Control" •<u>Gene microarrays</u> | <ul style="list-style-type: none"> •Examine the proteins in a cell, tissue, fluid sample •Proteins determine what is happening now •Comparison of "Disease" and "Control" •Disease-related •<u>"Proteome"</u> |
| <div style="border: 1px solid black; padding: 5px; width: fit-content; margin: 0 auto;"> <p><u>Snap shots of one point in time.</u> Poor agreement (17%) RNAi Post-translational modifications</p> </div> | | |